Shanghai Fosun Kairos Biotechnology

Shanghai Fosun Kairos Biotechnology is a joint venture between Fosun Pharma and the US-based biotech Kairos Pharma. The company focuses on the development and commercialization of innovative small molecule therapies for hematologic malignancies and other oncology indications. Its lead candidate, K-7174, is a first-in-class small molecule inhibitor targeting GATA-1 and the proteasome, currently being evaluated in clinical trials for the treatment of relapsed or refractory multiple myeloma. The company leverages Fosun Pharma's extensive clinical development and commercialization infrastructure in China alongside Kairos's novel drug discovery platform.